AMRN - Amarin Corporation plc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Amarin Corporation plc

2 Pembroke House
Upper Pembroke Street 28-32
Dublin 2
353 1 669 9020

Full Time Employees530

Key Executives

NameTitlePayExercisedYear Born
Mr. John F. TheroPres, CEO & Director1.39M7.22M1961
Mr. Michael W. KalbCFO, Sr. VP & Assistant Sec.676.23k1.23M1971
Dr. Steven B. KetchumPres of R&D, Sr. VP and Chief Scientific Officer738.33k9.09M1965
Mr. Joseph T. KennedyExec. VP, Gen. Counsel & Strategic Initiatives and Sec.772.14k10.13M1968
Ms. Elisabeth SchwartzSr. Director of Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. Amarin Corporation plc sells its products principally to wholesalers and specialty pharmacy providers through direct sales force. It has a collaboration with Mochida Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Biologix FZCo, and HLS Therapeutics, Inc. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Corporate Governance

Amarin Corporation plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.